Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States - PubMed (original) (raw)

Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States

Jessica A Davila et al. Hepatology. 2010 Jul.

Abstract

Surveillance for hepatocellular carcinoma (HCC) in patients with cirrhosis is recommended but may not be performed. The extent and determinants of HCC surveillance are unknown. We conducted a population-based United States cohort study of patients over 65 years of age to examine use and determinants of prediagnosis surveillance in patients with HCC who were previously diagnosed with cirrhosis. Patients diagnosed with HCC during 1994-2002 were identified from the linked Surveillance, Epidemiology, and End-Results registry-Medicare databases. We identified alpha-fetoprotein (AFP) and ultrasound tests performed for HCC surveillance, and examined factors associated with surveillance. We identified 1,873 HCC patients with a prior diagnosis of cirrhosis. In the 3 years before HCC, 17% received regular surveillance and 38% received inconsistent surveillance. In a subset of 541 patients in whom cirrhosis was recorded for 3 or more years prior to HCC, only 29% received routine surveillance and 33% received inconsistent surveillance. Among all patients who received regular surveillance, approximately 52% received both AFP and ultrasound, 46% received AFP only, and 2% received ultrasound only. Patients receiving regular surveillance were more likely to have lived in urban areas and had higher incomes than those who did not receive surveillance. Before diagnosis, approximately 48% of patients were seen by a gastroenterologist/hepatologist or by a physician with an academic affiliation; they were approximately 4.5-fold and 2.8-fold, respectively, more likely to receive regular surveillance than those seen by a primary care physician only. Geographic variation in surveillance was observed and explained by patient and physician factors.

Conclusion: Less than 20% of patients with cirrhosis who developed HCC received regular surveillance. Gastroenterologists/hepatologists or physicians with an academic affiliation are more likely to perform surveillance.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: No conflicts of interest exist for Drs. Davila, Morgan, Richardson, Du, McGlynn, or El-Serag.

Comment in

References

    1. El Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139(10):817–823. - PubMed
    1. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004;127(5):1372–1380. - PubMed
    1. El Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160(21):3227–3230. - PubMed
    1. Hassan MM, Frome A, Patt YZ, El Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol. 2002;35(3):266–269. - PubMed
    1. Kulkarni K, Barcak E, El Serag H, Goodgame R. The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States. Aliment Pharmacol Ther. 2004;20(4):445–450. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources